Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 21, 2015BloodOpen Access

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMadeleine DuvicNorthwestern UniversityLPLauren Pinter‐BrownUniversity of California, IrvineFFFrancine M. FossYale Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Duvic et al. (2015) studied this question.

synapsesocial.com/papers/6aa8f23ad75aeabedda3356ahttps://doi.org/10.1182/blood-2014-09-600924
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD30+ Lymphomatoid Drug Reactions2013 · 38 citations
  2. 2Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors2010 · 524 citations
  3. 3Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine1999 · 729 citations
  4. 4Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome2008 · 193 citations
  5. 5Absence of CD26 Expression Is a Useful Marker for Diagnosis of T-Cell Lymphoma in Peripheral Blood2001 · 203 citations